Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0700-0.3900 (-8.74%)
At close: 04:00PM EDT
4.0900 +0.02 (+0.49%)
After hours: 04:27PM EDT
Advertisement

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees110

Key Executives

NameTitlePayExercisedYear Born
Mr. Cezar Andrei Floroiu M.B.A.CEO, Pres & Director674.23kN/A1973
Dr. Sean N. TuckerSr. VP & Chief Scientific Officer494.77k5791968
Dr. James F. Cummings M.D.Chief Medical Officer151.95kN/A1966
Mr. Fuad AhmadInterim CFO and Principal Financial & Accounting OfficerN/AN/A1970
Mr. Edward B. BergSr. VP & Gen. CounselN/AN/A1964
Ms. Shaily Jaini GargSr. VP of Clinical Devel. & Project ManagementN/AN/AN/A
Mr. Brant BiehnSr. VP of Bus. OperationsN/AN/AN/A
Dr. Rajesh Kapoor Ph.D.Sr. VP of QualityN/AN/AN/A
Mr. John M. Harland M.B.A., CPAConsultantN/AN/A1952
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Corporate Governance

Vaxart, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement